171 related articles for article (PubMed ID: 36053386)
1. Adenosine A
Waggan I; Rissanen E; Tuisku J; Joutsa J; Helin S; Parkkola R; Rinne JO; Airas L
J Neurol; 2023 Jan; 270(1):300-310. PubMed ID: 36053386
[TBL] [Abstract][Full Text] [Related]
2. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
3. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease.
Waggan I; Rissanen E; Tuisku J; Matilainen M; Helin S; Parkkola R; Rinne JO; Airas L
Parkinsonism Relat Disord; 2021 May; 86():40-44. PubMed ID: 33831661
[TBL] [Abstract][Full Text] [Related]
4. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
5. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.
Mishina M; Ishiwata K; Naganawa M; Kimura Y; Kitamura S; Suzuki M; Hashimoto M; Ishibashi K; Oda K; Sakata M; Hamamoto M; Kobayashi S; Katayama Y; Ishii K
PLoS One; 2011 Feb; 6(2):e17338. PubMed ID: 21386999
[TBL] [Abstract][Full Text] [Related]
7. Boolean analysis shows a high proportion of dopamine D
Rivas-Santisteban R; Rico AJ; Muñoz A; Rodríguez-Pérez AI; Reyes-Resina I; Navarro G; Labandeira-García JL; Lanciego JL; Franco R
Neurobiol Dis; 2023 Nov; 188():106341. PubMed ID: 37918757
[TBL] [Abstract][Full Text] [Related]
8. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
9. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
10. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
11. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
12. Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression.
Le Moine C; Svenningsson P; Fredholm BB; Bloch B
J Neurosci; 1997 Oct; 17(20):8038-48. PubMed ID: 9315922
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A
Waggan I; Rissanen E; Tuisku J; Matilainen M; Parkkola R; Rinne JO; Airas L
Parkinsonism Relat Disord; 2023 Aug; 113():105766. PubMed ID: 37480614
[TBL] [Abstract][Full Text] [Related]
14. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
Mori A; Shindou T
Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A antagonists in Parkinson's disease: what's next?
Hickey P; Stacy M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
[TBL] [Abstract][Full Text] [Related]
16. Allosteric Interactions between Adenosine A
Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
[TBL] [Abstract][Full Text] [Related]
17. A(2A) adenosine receptors and Parkinson's disease severity.
Casetta I; Vincenzi F; Bencivelli D; Corciulo C; Gentile M; Granieri E; Borea PA; Varani K
Acta Neurol Scand; 2014 Apr; 129(4):276-81. PubMed ID: 24032478
[TBL] [Abstract][Full Text] [Related]
18. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function.
Rosin DL; Hettinger BD; Lee A; Linden J
Neurology; 2003 Dec; 61(11 Suppl 6):S12-8. PubMed ID: 14663003
[TBL] [Abstract][Full Text] [Related]
19. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Pinna A; Wardas J; Simola N; Morelli M
Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
[TBL] [Abstract][Full Text] [Related]
20. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
